What question did this study set out to answer?

This research aims to assess the efficacy of bulumtatug fuvedotin plus toripalimab in perioperative muscle-invasive bladder cancer patients.

May 29, 2026

Bulumtatug fuvedotin (BFv; 9MW2821) plus toripalimab in perioperative patients with muscle-invasive bladder cancer (MIBC): Results of cohort A from a phase 2 study.

Key Points

This research aims to assess the efficacy of bulumtatug fuvedotin plus toripalimab in perioperative muscle-invasive bladder cancer patients.
Cohort A enrolled patients with MIBC (cT2-4aN0-1M0) for neoadjuvant treatment with BFv plus toripalimab.
Patients received 4 cycles of therapy pre-surgery, followed by radical cystectomy and pelvic lymph node dissection.
Post-surgery, patients continued with BFv and toripalimab for 6 cycles, then transitioned to toripalimab alone for 11 cycles.
Pathological complete response (pCR) rate was 66.7% (4/6, 95% CI 22.3-95.7).
Pathological downstaging (PDS) rate was 83.3% (5/6, 95% CI 35.9-99.6).
Safety profile was aligned with previous studies, with no new safety signals observed.

Abstract

4609 Background: Radical cystectomy with pelvic lymph node dissection (RC+PLND) has always been the standard treatment for MIBC. Perioperative treatment, especially cisplatin-based neoadjuvant therapy, could reduce the risk of tumor recurrence effectively and prolong the survival of patients. BFv, a novel Nectin-4 antibody-drug conjugate, combined with toripalimab, has demonstrated promising efficacy and safety profile in advanced urothelial cancer patients. This provides possibilities for the perioperative treatment of MIBC. Here we report the preliminary results of BFv plus toripalimab in patients with perioperative MIBC (cohort A). Methods: Patients with MIBC (cT2-4aN0-1M0) can be enrolled in cohort A. Eligible patients will receive BFv plus toripalimab for 4 cycles in neoadjuvant stage, and then proceed with RC+PLND. After surgery, patients will receive BFv plus toripalimab for 6 cycles and toripalimab only for the next 11 cycles in the adjuvant stage. The primary endpoint was pathological complete response (pCR). Main secondary endpoints were pathological downstaging (PDS) rate and disease-free survival (DFS), overall survival (OS) and safety. Results: As of 4 Jan 2026, 32 patients were enrolled in the cohort A. 7 patients had completed neoadjuvant therapy and 6 of them were performed with RC+PLND. One patient achieved CR in the neoadjuvant stage and refused to undergo the surgery. pCR rate was 66.7% (4/6, 95%CI 22.3-95.7), PDS rate was 83.3% (5/6, 95%CI 35.9-99.6). DFS and OS were not mature. Safety profile was consist with previous study. No new safety signals of BFv or toripalimab were observed in this study. Conclusions: This study showed remarkable preliminary efficacy of BFv plus toripalimab in perioperative patients with MIBC. It may offer a new choice for MIBC patients and deserve to be further investigation. Clinical trial information: NCT07314723 .

KI fragen

Bookmark

Cite This Study

Liu et al. (Wed,) studied this question.

synapsesocial.com/papers/6a192dbbfab5b468c4416922 https://doi.org/https://doi.org/10.1200/jco.2026.44.16_suppl.4609

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

KI fragen

Bookmark